IRCT20150929024266N5招募中3 期
Comparing the effect of neoadjuvant temozolomide before chemoradiotherapy with chemoradiotherapy followed by adjuvant temozolomide on progression free survival in patients with Glioblastoma
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 134
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 80 years（—）
- 性别
- All
入选标准
- •Histologically proven glioblastoma grade IV: GBM
- •Age 18 - 80 years old
- •Performance status WHO 0-2
- •Men and women of child bearing potential must be using adequate contraception
- •Normal organ function, except if abnormal due to tumor involvement Patient
排除标准
- •Prior chemotherapy or radiotherapy for malignant glioma
- •Any other active malignancies within the last 5 years, except adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ
- •Pregnancy or breast feeding
- •Any condition (medical, social, psychological) which would prevent adequate information and follow up
- •Platelet count (TPK) <100 x 10^9/L
- •Hemoglobin (Hb) < 90 g/L
- •Neutrophils: < 1.5 x 10^3/mm3 or LPK < 3.0 x 10^9/L
- •Serum creatinine and bilirubin > 1.5 times the upper limit of normal (ULN)
- •Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) >3 x
研究者
相似试验
进行中（未招募）
不适用
Phase I/II study on concomitant and adjuvant Temozolomide and Radiotherapy with or without PTK787/ZK222584 in newly diagnosed GBMGlioblastoma multiformeEUCTR2004-003896-35-DEEuropean Organisation for Research and Treatment of Cancer220
进行中（未招募）
不适用
Phase I/II study on concomitant and adjuvant Temozolomide and Radiotherapy with or without PTK787/ZK222584 in newly diagnosed GBMGlioblastoma multiformeEUCTR2004-003896-35-GBEuropean Organisation for Research and Treatment of Cancer220
进行中（未招募）
1 期
Phase I/II study on concomitant and adjuvant Temozolomide and Radiotherapy with or without PTK787/ZK222584 in newly diagnosed GBMMedDRA version: 7.1Level: PTClassification code 10018337Glioblastoma multiformeEUCTR2004-003896-35-ATEuropean Organisation for Research and Treatment of Cancer220
进行中（未招募）
不适用
Phase I/II study on concomitant and adjuvant Temozolomide and Radiotherapy with or without PTK787/ZK222584 in newly diagnosed GBMGlioblastoma multiformeEUCTR2004-003896-35-BEEuropean Organisation for Research and Treatment of Cancer220
进行中（未招募）
不适用
Phase I/II study on concomitant and adjuvant Temozolomide and Radiotherapy with or without PTK787/ZK222584 in newly diagnosed GBMMedDRA version: 6.1Level: PTClassification code 10018337Glioblastoma multiformeEUCTR2004-003896-35-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER220